Welcome to CDC stacks | Economic Model for Emergency Use Authorization of Intravenous Peramivir - 33621 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Economic Model for Emergency Use Authorization of Intravenous Peramivir
  • Published Date:
    Jan 2011
  • Source:
    Am J Manag Care. 17(1):e1-e9.
Filetype[PDF-430.99 KB]

  • Pubmed ID:
  • Pubmed Central ID:
  • Description:

    To develop 3 computer simulation models to determine the potential economic effect of using intravenous (IV) antiviral agents to treat hospitalized patients with influenza-like illness, as well as different testing and treatment strategies.

    Study Design

    Stochastic decision analytic computer simulation model.


    During the 2009 influenza A(H1N1) pandemic, the Food and Drug Administration granted emergency use authorization of IV neuraminidase inhibitors for hospitalized patients with influenza, creating a need for rapid decision analyses to help guide use. We compared the economic value from the societal and third-party payer perspectives of the following 4 strategies for a patient hospitalized with influenza-like illness and unable to take oral antiviral agents: Strategy 1: Administration of IV antiviral agents without polymerase chain reaction influenza testing. Strategy 2: Initiation of IV antiviral treatment, followed by polymerase chain reaction testing to determine whether the treatment should be continued. Strategy 3: Performance of polymerase chain reaction testing, followed by initiation of IV antiviral treatment if the test results are positive. Strategy 4: Administration of no IV antiviral agents. Sensitivity analyses varied the probability of having influenza (baseline, 10%; range, 10%–30%), IV antiviral efficacy (baseline, oral oseltamivir phosphate; range, 25%–75%), IV antiviral daily cost (range, $20–$1000), IV antiviral reduction of illness duration (baseline, 1 day; range, 1–2 days), and ventilated vs nonventilated status of the patient.


    When the cost of IV antiviral agents was no more than $500 per day, the incremental cost-effectiveness ratio for most of the IV antiviral treatment strategies was less than $10,000 per quality-adjusted life-year compared with no treatment. When the cost was no more than $100 per day, all 3 IV antiviral strategies were even more cost-effective. The order of cost-effectiveness from most to least was strategies 3, 1, and 2. The findings were robust to changing risk of influenza, influenza mortality, IV antiviral efficacy, IV antiviral daily cost, IV antiviral reduction of illness duration, and ventilated vs nonventilated status of the patient for both societal and third-party payer perspectives.


    Our study supports the use of IV antiviral treatment for hospitalized patients with influenza-like illness.

  • Document Type:
  • Collection(s):
  • Funding:
    5R01LM009132-03/LM/NLM NIH HHS/United States
    5U54GM088491-02/GM/NIGMS NIH HHS/United States
    P01 HK000086/HK/PHITPO CDC HHS/United States
    U54 GM088491/GM/NIGMS NIH HHS/United States
    R01 LM009132/LM/NLM NIH HHS/United States
    5P01HK000086-02/HK/PHITPO CDC HHS/United States
No Related Documents.
You May Also Like: